
Oxeia Biopharmaceuticals announces Phase II trial for concussion treatment
Oxeia Biopharmaceuticals is a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury. It has announced the initiation of a Phase II clinical trial of OXE103 for treating concussion. The Phase II clinical study is being conducted by Dr. Michael Rippee,… Read More















